<DOC>
	<DOCNO>NCT00394095</DOCNO>
	<brief_summary>The primary objective study examine efficacy topiramate combination olanzapine prevention weight gain youth bipolar disorder . The secondary objective examine tolerability topiramate combination olanzapine prevention weight gain youth bipolar disorder .</brief_summary>
	<brief_title>Topiramate v . Placebo Preventing Weight Gain Bipolar Disorder Treated With Olanzapine</brief_title>
	<detailed_description>After consent screening , patient initiate 5mg 10mg per day olanzapine . Olanzapine dose titrate 10-20 mg olanzapine one week , maximum 20mg day 21 . Patients also receive either topiramate ( 25mg bid titrate 18 day 150 mg bid . flexibility titrate 200mg bid ) match placebo . Topiramate initiate dose 25 mg bid increase 25 mg bid every three day tolerate . Patients evaluate blinded ( treatment status adverse event ) rater .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>1 . Male female patient , age 1018 year . 2 . Female patient menarche must use medically accept mean contraception ( e.g . oral contraceptive , DepoProvera , abstinence ) . 3 . Each patient 's authorized legal guardian must understand nature study must provide write informed consent . Each patient must also give assent study participation . 4 . Patients must diagnosis Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIVTR ) bipolar disorder , type I currently display acute manic mixed episode determine KSADS ( Geller et al 2000 ) . 5 . Patients must baseline ( day 0 ) Young Mania Rating Scale score least 16 . 6 . Subjects fluent English . 1 . Female patient either pregnant lactating . 2 . Clinically significant unstable hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , immunologic , hematologic systemic medical condition . 3 . Any history current past diabetes treat pharmacological intervention . 4 . Neurological disorder include epilepsy , stroke , severe head trauma . 5 . Clinically significant laboratory abnormality ( &gt; 3 time upper limit normal ) , follow test : CBC differential , electrolytes , BUN , creatinine , hepatic transaminase , lipid profile , fast glucose , urinalysis , thyroid index . Clinically abnormal ECG . 6 . Manic mixed episode due general medical condition substanceinduced mania ( DSMIVTR ) . 7 . Mental retardation ( IQ &lt; 70 ) . 8 . History hypersensitivity intolerance olanzapine topiramate . 9 . Prior history olanzapine topiramate nonresponse allergic reaction . 10 . DSMIV substance ( except nicotine caffeine ) dependence within past 3 month . 11 . Judged clinically suicidal risk ( define active suicidal ideation , intent plan , serious suicide attempt within 30 day , baseline Children 's Depression Rating Scale suicide score &gt; 3 ) . 12 . Treatment injectable depot neuroleptic within less one dosing interval depot neuroleptic injection day 0 . 13 . Treatment concurrent mood stabilizer anticonvulsant , benzodiazepine ( except describe ) , psychostimulants , guanethidine , guanadrel , antidepressant . 14 . Schizophrenia psychotic disorder ( include schizophreniform disorder , schizoaffective disorder , delusional disorder , brief psychotic disorder , share psychotic disorder , psychotic disorder due general medical condition , substanceinduced psychotic disorder , psychotic disorder otherwise specify ) define DSMIV . 15 . Major depressive disorder , dysthymic disorder , depressive disorder otherwise specify .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Weight Gain</keyword>
</DOC>